New hope for GIST: velzatinib takes on imatinib in major trial
NCT ID NCT07585266
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new drug, velzatinib, to the standard drug imatinib in 800 people with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The goal is to see if velzatinib can delay tumor growth better than imatinib. Participants have not had prior treatment for advanced GIST.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Velzatinib (a targeted drug) compared to imatinib (standard targeted drug)
What this could lead to
If velzatinib works better than imatinib, it could become a new first-line treatment that delays tumor growth longer for people with advanced GIST.
What could go wrong
This is an early-stage comparison; velzatinib may not prove superior or may have unexpected side effects. Results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••